Table 1.
Baseline demographics and characteristics of IPL alone group and IPL with topical steroid group.
| IPL alone (n = 238) | IPL + steroid (n = 260) | p-value | |
|---|---|---|---|
| Age (years) | 50.29 ± 16.04 | 50.43 ± 14.63 | 0.919 |
| Sex (n, % of female) | 184 (77.3) | 186 (71.5) | 0.151 |
| Predisposing factors (n, %) | |||
| Allergy | 120 (40.4) | 136 (42.3) | 0.720 |
| Rosacea | 71 (29.8) | 62 (23.8) | 0.132 |
| Sjogren syndrome | 12 (5.0) | 14 (5.4) | 0.864 |
| Acne medication | 10 (4.2) | 11 (4.2) | 0.987 |
| Hormonal treatment | 6 (2.5) | 5 (1.9) | 0.650 |
| OSDI (scores) | 28.53 ± 7.16 | 27.62 ± 8.13 | 0.518 |
| Meibomian gland indices | |||
| Meibomian gland expressibility (grades) | 2.90 ± 1.06 | 2.79 ± 1.12 | 0.262 |
| Meibum quality (grades) | 2.99 ± 1.18 | 2.83 ± 1.32 | 0.221 |
| Lid margin deformity (n, %) | |||
| Vascular enlargement | 142 (59.7) | 169 (65.0) | 0.219 |
| Notching | 36 (15.1) | 40 (15.3) | 0.936 |
| Plugging | 47 (19.7) | 52 (20.0) | 0.944 |
| Mucocutaneous junction shift | 60 (25.2) | 77 (29.6) | 0.271 |
| Tear meniscus height (nm) | 207.21 ± 31.96 | 205.60 ± 32.07 | 0.575 |
| SICCA (scores) | 1.24 ± 0.41 | 1.30 ± 0.38 | 0.091 |
| CCLRU grading scale (grades) | |||
| Bulbar redness | 2.71 ± 1.23 | 2.73 ± 1.15 | 0.851 |
| Palpebral conjunctival redness | 2.85 ± 1.63 | 2.84 ± 1.73 | 0.947 |
| Palpebral conjunctival roughness | 2.23 ± 1.01 | 2.35 ± 0.89 | 0.159 |
∗ Statistically significance.